Article Text

Download PDFPDF
Lack of effect from mitomycin c plus 5-fluorouracil in platin-resistant ovarian cancer: a phase II study
  2. H. HAVSTEEN and
  3. C. KAMBY*
  1. *Department of Oncology, Copenhagen University Hospital in Herlev, Herlev
  2. Department of Oncology, Aahus University Hospital, Aahus, Denmark
  1. Address for correspondence: Dr V. Vestermark, Sortedam Dossering 63B,2., DK-2100 Copenhagen 0, Denmark.


Sixteen patients with advanced ovarian cancer were included in a phase II study with mitomycin c (MMC) plus 5-fluorouracil (5-FU). All patients had previously received platin-based combination therapy, but were resistant to this treatment. A MMC 10 mg m−2 intravenous (iv) bolus was given on day 1 every 6 weeks, and 5-FU 1000 mg m−2 was given iv on days 1–3 every 3 weeks, as a continuous infusion over 72 h. Fifteen patients were evaluable for response. There were no responders, neither partial nor complete. The median survival was 6 months. The toxicity was primarily bone marrow suppression. The treatment was generally well tolerated. No patients had grade 4 toxicity and only five had grade 3 hematologic toxicity. In conclusion, we find the present regimen to be ineffective in the treatment of platin-resistant ovarian cancer.

  • 5-fluorouracil
  • mitomycin c
  • platin-resistant ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.